Supernus Pharmaceuticals SUPN Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Supernus Pharmaceuticals (SUPN) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $59.22M in Q1 2026.
- How has Supernus Pharmaceuticals's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
- Supernus Pharmaceuticals's proceeds from maturities, prepayments and calls of debt securities, available-for-sale decreased by 62.1% year-over-year, from $156.2M to $59.22M.
- What is the long-term trend for Supernus Pharmaceuticals's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Over 2 years (2022 to 2025), Supernus Pharmaceuticals's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a 101.5% compound annual growth rate (CAGR), from $190.74M to $774.48M.